S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.17%) $0.928
USD/NOK
(0.40%) $10.88
USD/GBP
(-0.01%) $0.792
USD/RUB
(-0.22%) $92.37

Realtime updates for Genfit SA [GNFT]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Last Updated28 Mar 2024 @ 16:00

1.14% $ 3.56

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis...

Stats
Today's Volume 211.00
Average Volume 17 740.00
Market Cap 176.97M
EPS $0 ( 2023-07-13 )
Next earnings date ( $0 ) 2024-04-11
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -4.29
ATR14 $0 (0.00%)

Genfit SA Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Genfit SA Financials

Annual 2022
Revenue: $20.20M
Gross Profit: $19.95M (98.77 %)
EPS: $-0.480
Q3 2023
Revenue: $2.82M
Gross Profit: $2.82M (100.00 %)
EPS: $0
Q2 2023
Revenue: $11.48M
Gross Profit: $7.56M (65.81 %)
EPS: $-0.420
Q1 2023
Revenue: $7.56M
Gross Profit: $7.56M (100.00 %)
EPS: $-0.210

Financial Reports:

No articles found.

Genfit SA

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators